ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global ...

At American Heart Association conference in New Orleans, Crispr Therapeutics CRSP said a single dose of its gene-editing drug ...

From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.

New study has discovered a groundbreaking technology that is showing remarkable success in significantly reducing bad ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

Phase 1 data showed CRISPR’s one-time treatment, CTX310, produced sharp, dose-dependent reductions in triglycerides and LDL cholesterol with a strong safety profile. ・The company plans to advance the ...

A research team from the University of Osaka, in collaboration with the Massachusetts Institute of Technology, has uncovered ...

The company scans entire proteins with CRISPR to find functional vulnerabilities, then hunts for molecules that exploit them ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...

The field of infectious disease research is undergoing rapid transformation due to the continuous emergence of novel bacterial threats and the accelerating ...